Litigation Details for Rite Aid Corporation v. Endo Health Solutions Inc. (N.D. Ill. 2015)
✉ Email this page to a colleague
Rite Aid Corporation v. Endo Health Solutions Inc. (N.D. Ill. 2015)
| Docket | ⤷ Sign Up | Date Filed | 2015-04-23 |
| Court | District Court, N.D. Illinois | Date Terminated | |
| Cause | 15:15 Antitrust Litigation | Assigned To | Harry Daniel Leinenweber |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 7,276,250 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Rite Aid Corporation v. Endo Health Solutions Inc.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Rite Aid Corporation v. Endo Health Solutions Inc. (N.D. Ill. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-04-23 | 1 | United States Patent No. 7,276,250 (the “‘250 patent”). The ‘143, ‘456, ‘933, and ‘250 patents are collectively…‘143 patent”), United States Patent No. 5,958,456 (the “‘456 patent”), and United States Patent No. 5,662,933…, and ‘933 patents as well as any continuations of those patents and to any pending patent applications… risk (while the patent litigation was still pending); (b) after winning the patent litigation; or (c…expiration of the listed patents. If a brand manufacturer obtains a patent after FDA approval of an NDA | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
